Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold play in the AI sector.
In a span of a week, Tempus AI, Inc. (NASDAQ:TEM) made two announcements that add to its growing pipeline of clinical and pharma partnerships.
The freshest update came on May 21, 2026, when Tempus AI, Inc. (NASDAQ:TEM) launched the ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer (mHSPC). The CLIA-certified and CAP-accredited prognostic test is the first externally developed digital pathology algorithm made clinically available through the Tempus ecosystem.
It works by analyzing a patient’s clinical information and histopathology biopsy image to extract a personalized risk estimate of prostate cancer-specific mortality. Tempus AI, Inc. (NASDAQ:TEM) said the test fills a gap for approximately 25,000 patients newly diagnosed with metastatic prostate cancer in the U.S. each year. Clinicians can order it as an add-on to Tempus’ solid tumor portfolio across all ordering modalities. Additionally, its output can be paired with Tempus’ next-generation sequencing (NGS) assay results to provide a fuller picture of a patient’s disease.
That came a week after Tempus AI, Inc. (NASDAQ:TEM) announced an expanded collaboration with Bristol Myers Squibb on May 14, 2026.
The two companies said they would apply AI and multimodal real-world data across five initial clinical trial programs, with the goal of improving what they called the Probability of Technical and Regulatory Success. Using Lens, Tempus’ AI-enabled analytical platform, the partners are targeting programs in lung, colon, and prostate cancers, as well as Alzheimer’s Disease.
The initiative builds on an earlier arrangement that deployed Tempus AI, Inc. (NASDAQ:TEM)’s Next Pathways program across 13 community-based health systems for patients with advanced non-small cell lung cancer (aNSCLC).
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.
While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
